As of 2025-09-17, the Intrinsic Value of Nirvana Life Sciences Inc (NIRV.CN) is -0.28 CAD. This NIRV.CN valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.08 CAD, the upside of Nirvana Life Sciences Inc is -455.60%.
Based on its market price of 0.08 CAD and our intrinsic valuation, Nirvana Life Sciences Inc (NIRV.CN) is overvalued by 455.60%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.28 - -0.28 | -0.28 | -455.60% |
| DDM - Stable | (0.27) - (0.54) | (0.40) | -606.1% |
| DDM - Multi | (0.59) - (0.92) | (0.72) | -994.7% |
| Market Cap (mil) | 0.48 |
| Beta | 2.71 |
| Outstanding shares (mil) | 6.03 |
| Enterprise Value (mil) | 0.58 |
| Market risk premium | 5.10% |
| Cost of Equity | 16.11% |
| Cost of Debt | 5.00% |
| WACC | 15.42% |